TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer (DEBIRITUX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01060423
Recruitment Status : Terminated (Terminated due to poor subject enrolment)
First Posted : February 2, 2010
Last Update Posted : October 26, 2016
Biocompatibles UK Ltd
Information provided by (Responsible Party):
Hans-Joachim Schmoll, MD, Martin-Luther-Universität Halle-Wittenberg

January 27, 2010
February 2, 2010
October 26, 2016
February 2010
December 2012   (Final data collection date for primary outcome measure)
Progression free survival rate [ Time Frame: 6 months after first administration of study medication ]
Progression free survival rate [ Time Frame: 6 months ]
Complete list of historical versions of study NCT01060423 on Archive Site
  • Tumour Response (according to RECIST v1.1) [ Time Frame: every three months up to progression of disease, maximum 12 months from the date of patient enrolment ]
    extent of treated lesions
  • Time to progression [ Time Frame: every three months, until death of patient, maximum 12 months from the date of patient enrolment ]
  • Number of adverse events in study patients [ Time Frame: whole study, every two weeks until 28 days from the date of last administration of study medication ]
  • Local tumour response [ Time Frame: every three months up to progression of disease, maximum 12 months from the date of patient enrolment ]
    extent of necrosis in the treated lesions
  • Overall survival [ Time Frame: every three months, until death of patient, maximum 12 months from the date of last patient enrolment ]
  • Safety assessments will include physical examinations, vital signs, clinical laboratory profile and monitoring of adverse events [ Time Frame: whole study, every two weeks ]
  • Tumour Response (according to RECIST v1.1)and Local tumour response (extent of necrosis in the treated lesions) [ Time Frame: every three months ]
  • Time to progression, Overall survival [ Time Frame: every three months ]
Not Provided
Not Provided
TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
A Randomized Phase II Trial of Irinotecan Drug-eluting Beads Administered by Hepatic Chemoembolization With Intravenous Cetuximab (DEBIRITUX) Versus Systemic Treatment With Intravenous Cetuximab and Irinotecan in Patients With Refractory Metastatic Colorectal Cancer and K-ras Wild-type Tumours

The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in combination with intravenous cetuximab versus intravenous irinotecan in combination with intravenous cetuximab in the treatment of patients with unresectable liver metastases from colorectal cancer.

Secondary objectives are safety and tolerability of hepatic chemoembolization and the question if the addition of aprepitant to standard antiemetic prophylaxis in patients treated by hepatic chemoembolization is safe and will reduce the rate of acute and delayed nausea and emesis.

About half of patients with newly diagnosed colorectal cancer will develop metastatic disease and, however, in spite of the significant progress in the therapeutical strategies for metastatic disease, virtually all patients will eventually succumb to their illness. Based on prior clinical data there is a good rationale for the expectation that the combination of systemic chemotherapy and arterial chemoembolization with drug eluting beads may be effective in the setting of patients with unresectable or chemorefractory liver metastases. The aim of this study is therefore to assess whether the combination of Irinotecan eluting beads and intravenous cetuximab is safe and effective in the treatment of patients with unresectable liver metastases from refractory colorectal cancer and will result in a prolongation of disease control when compared to standard systemic treatment with intravenous irinotecan and intravenous cetuximab. In this patient group, intravenous irinotecan plus intravenous cetuximab may represent the "standard of care", with a previously described activity. The patient group is defined in terms of pretreatment, and the scientific question is whether the way of irinotecan administration by eluting beads in feasible and somehow beneficial.
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Colorectal Cancer
  • Drug: Cetuximab
    Starting dose of 400mg/m2, followed by weekly 250mg/m2
    Other Name: Erbitux
  • Drug: Irinotecan
    Irinotecan 180 mg/m² to be administered every two weeks
  • Device: Irinotecan eluting BEADS
    A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
    Other Name: DC Bead
  • Experimental: hepatic TACE with irinotecan eluting beads and iv cetuximab
    Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)
    • Drug: Cetuximab
    • Device: Irinotecan eluting BEADS
  • Active Comparator: iv cetuximab and irinotecan
    systemic treatment with intravenous cetuximab and irinotecan
    • Drug: Cetuximab
    • Drug: Irinotecan
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2015
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with confirmed diagnosis of stage IV (UICC) colorectal cancer with unresectable liver metastases (primary tumour may be present) and k-ras wild-type tumours
  2. Patients had been treated and shown to be refractory to 5-FU (Capecitabine allowed)/oxaliplatin and/or 5-FU/irinotecan. Prior therapy with VEGF-inhibitors (e.g bevacizumab) is allowed
  3. Patients with at least one measurable liver metastasis, with size > 1cm (RECIST criteria)
  4. Patients with liver only or liver dominant disease (defined as ≥ 50 % tumour burden confined to the liver)
  5. Patients with a portal vein not interfering with transarterial chemoembolization (e.g. no thrombosis) as judged by the investigator
  6. ECOG Performance status ≤ 2
  7. Life expectancy > 3 months
  8. Age ≥ 18 years.
  9. At least 4 weeks since last administration of last chemotherapy and/or radiotherapy (bone metastases may be allowed)
  10. Patients who received VEGF-inhibition (e.g. with bevacizumab) in prior therapy are eligible if stopped since 4-6 weeks before randomization
  11. Haematologic function: ANC ≥ 1.5 x 109/L, platelets ≥ 75 x109/L
  12. INR < 1.5 (patients on therapeutic anticoagulants are not eligible)
  13. Adequate liver function as measured by serum transaminases (AST & ALT) ≤ 3 x ULN and total bilirubin ≤ 1.5 x ULN
  14. Adequate renal function: Serum creatinine ≤ 1.5 x ULN
  15. Normal level of serum magnesium
  16. Women of child bearing potential and fertile men are required to use effective contraception (negative serum βHCG for women of child-bearing age
  17. Signed, written informed consent

Exclusion Criteria:

  1. Presence of CNS metastases
  2. Contraindications to irinotecan therapy (Chronic inflammatory bowel disease and/or bowel obstruction, history of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate)
  3. Active bacterial, viral or fungal infection within 72 hours of study entry
  4. Women who are pregnant or breast feeding
  5. Allergy to contrast media
  6. Presence of another concurrent malignancy. Prior malignancy in the last 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix
  7. Any contraindication for hepatic embolisation procedures:

    • Large shunt as determined by the investigator (pretesting with lung perfusion scan not required)
    • Severe atheromatosis
    • Hepatofugal blood flow
  8. Other significant medical or surgical condition, or any medication or treatment, that would place the patient at undue risk, that would preclude the safe use of chemoembolization or would interfere with study participation
  9. Known hypersensitivity or contraindication to the drugs used in the trial (eg: cetuximab, 5-HT3 receptor antagonist, dexamethasone, or any component of aprepitant)
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
EudraCT: 2009-014728-44
Not Provided
Not Provided
Hans-Joachim Schmoll, MD, Martin-Luther-Universität Halle-Wittenberg
Hans-Joachim Schmoll, MD
Biocompatibles UK Ltd
Principal Investigator: Dirk Arnold, MD Universitätsklinikum Eppendorf, Universitäres Cancer Center
Martin-Luther-Universität Halle-Wittenberg
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP